Prostate Cancer Genomic Classifier VL

The Benefit of ADT Treatment Intensification With Radiotherapy in Localized Prostate Cancer – Dan Spratt and Amar Kishan

Details
Daniel Spratt and Amar Kishan discuss a Lancet Oncology publication, on behalf of the MARCAP Consortium, titled "Androgen Deprivation Therapy Use and Duration with Definitive Radiotherapy for Localised Prostate Cancer: An Individual Patient Data Meta-Analysis." Led by Dr. Kishan, this individual patient data meta-analysis of relevant randomized trials aimed to quantify the benefit of various andro...

The Performance of a Genomic Classifier Score in the Phase 3 SAKK 09/10 in Patients with Biochemical Progression - Alan Dal Pra

Details
Alan Dal Pra joins Alicia Morgans in a discussion on the SAKK 09/10 trial presented at the 2021 ASTRO meeting. Dr. Alan Dal Pra highlights the efficacy of very intensive versus less intensive radiation in the biochemical recurrent prostate cancer population. This conversation also touches on Decipher® scores and PSA values in these patients. Biographies: Alan Dal Pra, MD, Assistant Professor and A...

Validation of Performance of the Decipher Biopsy Genomic Classifier in Intermediate-Risk Prostate Cancer: The Phase III Randomized Trial NRG Oncology/RTOG 0126 – Jeff Michalski

Details
Daniel Spratt and Jeff Michalski discuss the pivotal NRG Oncology RTOG 0126 trial from which Dr Michalski is the PI. This phase III randomized NRG/RTOG 0126 trial provides the first validation of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer. Dr. Spratt provides the background on the rationale for the NRG/RTOG 0126 and the results from the RTOG 0126 trial. They discus...

The Impact of Decipher Biopsy Testing on Clinical Outcomes in Localized Prostate Cancer – Randy A. Vince Jr.

Details
Daniel Spratt and Randy Vince discuss the impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer. This conversation starts off with a background on Decipher Biopsy testing and how it is used for men with prostate cancer. This then transitions into a discussion on the controls and background of how the study was set up. Dr. Vince then discusses some of the main findings...

High Risk Prostate Cancer and Genomics - Paul Nguyen & Alan Pollack

Details
Paul Nguyen and Alan Pollack join Alicia Morgans in a discussion on risk prognostication in high-risk prostate cancer. Dr. Nguyen discusses the role of genomics to risk-stratify high-risk prostate cancer patients and the role of Decipher at the time of biopsy. He reviews data from an oral presentation he delivered at the 2021 American Society for Radiation Oncology (ASTRO) annual meeting titled: V...

Personalized Hormone Therapy with Post-Operative Radiation Therapy and Validation of the Decipher Genomic Classifier in SAKK 09/10 Trial - Dan Spratt and Alan Dal Pra

Details
In this UroToday presentation Daniel Spratt, MD, and Alan Dal Pra, MD, share results from recent clinical trials that highlight the timing and patient selection for the personalization of hormone therapy with postoperative radiation therapy and the clinical implications for Decipher. Biographies: Daniel Spratt, MD, Vincent K. Smith Chair in Radiation Oncology, University Hospitals Seidman Cancer C...

When to Add ADT to Early or Late Salvage Radiation - Dan Spratt

Details
Daniel Spratt, MD, reviews the data from two trials that demonstrate the selection of patients for the addition of hormone therapy (ADT) to post-prostatectomy radiation therapy. Dr. Spratt discusses two phase three trials that have evaluated hormonal therapy in the postoperative RP setting with a rising PSA. The RTOG 9601 trial and the GETUG-AFU 16 trial are distinct from each other where the RTOG...

Clinical Case Discussions - "Rising PSA 18 Months Post RP and Timing of Radiotherapy" - Ashley Ross, Alan Dal Pra, and Dan Spratt

Details
Ashley Ross, MD, PhD, Alan Dal Pra, MD, and Daniel Spratt, MD, discuss two cases of patients each about 18 months post-prostatectomy with rising PSA, evaluating the timing to radiotherapy and the evidence to intensify with ADT. Biographies: Ashley Ross, MD, Ph.D., Associate Professor, Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois Alan Dal Pra, MD, A...

A Systematic Review of the Decipher® Genomic Classifier in Prostate Cancer - Ashley Ross & Daniel Spratt

Details
Ashley Ross is joined by Daniel Spratt presenting a European Association of Urology publication on A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer . In a field of rapidly acquiring data, among the challenges that motivated this systematic review was the breadth of papers and data being published. Dr. Spratt and colleagues sought to acquire the most up-to-...

Validation of a Prognostic Genomic Classifier in Salvage Radiotherapy Prostate Cancer from a Prospective Randomized Trial - Felix Feng

Details
Alicia Morgans is joined by Felix Feng to discuss his recent presentation on a new analysis from the Phase III RTOG 9601 trial. They discuss the application of using Decipher, a test based on gene expression profiles in primary tumors in prostate cancer, which adds significantly to identifying the men with the most aggressive disease. It drives the discussion to when we adopt genomic biomarkers in...
email news signup